IN RESPONSE: Dr. Finucane correctly points out that few data are available to guide the management of delirium in patients near the end of life. We strongly agree that research to guide the treatment of delirium is urgently needed, and this fact was a major area of emphasis in our article. However, in the absence of evidence from robust clinical trials, our recommendations are based on evidence provided by the medical literature, consensus of expert opinion, and our clinical experience in the care of patients at the end of life. In fact, the American College of Physicians-American Society of Internal Medicine End-of-Life Care Consensus Panel was convened to synthesize the best available evidence to guide end-of-life care. It was on the basis of the best available evidence that our recommendations were formulated.
We also agree with Dr. Finucane about the limitations of the clinical trial cited (1) . However, the recommendation supporting haloperidol was based not on this clinical trial alone but also on the consensus of palliative care clinicians as well as our own experience. Benzodiazepines are not recommended as a first-line treatment in the management of delirium near the end of life, since they are likely to produce sedation that many patients and families find unacceptable. When sedation is desirable, we prefer chlorpromazine, which produces sedation with less risk for respiratory depression. In general, however, we maintain that haloperidol offers the best balance of effectiveness and toxicity. We agree with Dr. Finucane that there is no current evidence to support the use of atypical antipsychotic agents. We also agree that treatment goals should always be set and that modification of the treatment regimen may be required to meet these goals. With regard to the biological plausibility of the effectiveness of haloperidol for treatment of delirium, several lines of evidence have suggested that imbalance or hyperactivity in the dopaminergic system may contribute to delirium (2, 3) . Thus, a dopamine-blocking agent such as haloperidol may well demonstrate beneficial effects. The benefits of haloperidol for the hallucinations, delusions, paranoia, and agitation that may accompany delirium are certainly in line with its well-documented effectiveness for similar symptoms of dementia as well as schizophrenia. Therefore, we continue to support and recommend haloperidol as first-line treatment for delirium at the end of life. We hope that future studies will be undertaken to provide a solid evidence base to guide end-of-life care. Veterans Affairs Medical Center  Philadelphia, PA 19104 Sharon Inouye, MD, MPH Yale University New Haven, CT 06520 study assessing the effects of low-and moderate-dose folic acid supplementation on endothelial function in persons 70 years of age or older. Homocysteine levels increase with age, and use of vitamin supplements is common in this age group because of perceived but untested health and cardioprotective benefits (2, 3) . Literature before the era of folic-acid flour fortification described total homocysteine levels that averaged approximately 13 mol/L in community-dwelling older adults (4). However, we screened 80 community-dwelling older men and women (mean age Ϯ SD, 76.5 Ϯ 4.8 years [range, 69 to 88 years]) who were not taking multivitamin or folic acid supplements and found that the total homocysteine level was only 9.6 Ϯ 2.5 mol/L (range, 5.2 to 20.0 mol/L); only 8 persons had levels of 12.0 mol/L or greater. Therefore, older adults are another patient population exposed to folic acid-fortified cereal grain flour in which the "homocysteine hypothesis" may not be able to be tested adequately. Infliximab Therapy for Complicated Sarcoidosis TO THE EDITOR: Yee and Pochapin (1) report a case of sarcoidosis that is noteworthy not only for the dramatic response to infliximab but also for the unusual presentation. As discussed, this case represents empirical evidence of a novel therapy. The results from many pathophysiologic studies make this therapeutic response entirely plausible. Gene polymorphisms of tumor necrosis factor-␣ (TNF-␣) that lead to elevated levels of circulating TNF-␣ have been found in patients with sarcoidosis, and TNF-␣ is expressed within sarcoid granulomas (2) .
David Casarett, MD, MA

Cynthia
Since the report describes such an unusual presentation for a case of sarcoidosis, it is worth reiterating that TNF-␣ might be the key not only to sarcoidosis but also to granuloma formation in general. Even in the absence of lymphocytes, TNF-␣ seems to be necessary and sufficient to induce granuloma formation (3) . Results of pathophysiologic studies, therefore, are consistent with the impression that there is significant overlap between the protean clinical manifestations of sarcoidosis and other granulomatous diseases. This fact impinges heavily on the differential diagnosis, particularly when the presentation is unusual. Although Yee and Pochapin are to be commended for their pursuit of the diagnosis and their innovative approach to therapy, it is surprising that they did not report the serum immunoglobulin levels. The granulomatous variant of common variable immunodeficiency can mimic sarcoidosis in almost every respect, except that common variable immunodeficiency is associated with IgG deficiency while sarcoidosis usually causes polyclonal hypergammaglobulinemia (4). Severe gastrointestinal involvement, even in the absence of overt infection, is certainly more common in common variable immunodeficiency than in sarcoidosis, and there is a paradoxical association between common variable immunodeficiency and humoral autoimmunity. Finally, granulomatous common variable immunodeficiency is also associated with elevated levels of TNF-␣ and has been shown to respond to TNF-␣ blockade (5).
Matthew C. Cook, MD, PhD, FRACP, FRCPA
The Canberra Hospital 2606 Woden ACT, Australia TO THE EDITOR: We read with interest Yee and Pochapin's report of treatment of complicated sarcoidosis with infliximab (1). The authors suggest that biological agents with specificity for TNF-␣ may represent a novel treatment for sarcoidosis. It is surprising, however, that the association of infliximab therapy with tuberculosis is not mentioned. Tuberculosis and sarcoidosis may present similarly, may be difficult to differentiate, and indeed may rarely coexist. Both diseases are characterized by granulomatous inflammation. However, while granulomas in sarcoidosis are central to its pathogenesis, granulomas in tuberculosis play a critical protective role. Macrophages are activated in the alveolar inflammation of active tuberculosis and release increased quantities of TNF-␣ (3). Tumor necrosis factor-␣-dependent expression of adhesion molecules is essential for the recruitment of mononuclear cells to form granulomas, where the close apposition of activated T cells and macrophages limits tissue damage and bacterial dissemination. Using a model of persistent murine tuberculosis, Mohan and colleagues (4) showed that TNF-␣ neutralization has been shown to cause fatal reactivation of tuberculosis (4) .
We recently treated a 35-year-old woman who developed reactivation of pulmonary tuberculosis after infliximab therapy for fistulizing Crohn disease. In December 2000, the Committee for Proprietary Medicinal Products of the European Medicines Evaluation Agency (EMEA) warned of 28 postmarketing reports of tuberculosis in patients treated with infliximab (9 in North America and 19 in Europe). One of these cases was fatal. The EMEA suggested discontinuing infliximab treatment if active tuberculosis is suspected, eval-uating patients for both active and inactive ("latent") tuberculosis before starting treatment with infliximab, and instructing patients to seek medical advice if signs or symptoms of tuberculosis appear. We believe that physicians should be aware of the risk for reactivation of tuberculosis in persons treated with infliximab, especially those with granulomatous diseases like Crohn disease and sarcoidosis, where tuberculosis could be the real culprit. We thank Dr. Cook and Dr. O'Connor and his colleagues for their interest in our article. Their comments underscore the diagnostic and therapeutic challenges associated with atypical presentations of granulomatous diseases. Dr. Cook insightfully points out that the granulomatous variant of common variable immunodeficiency can be confused for sarcoidosis. Although not presented in our article, immunofixation electrophoresis of our patient's serum in fact demonstrated polyclonal hypergammaglobulinemia, and while serum IgG and IgM levels were not quantitatively assessed, serum IgA levels (determined in anticipation of possible intravenous gammaglobulin therapy for the antiphospholipid antibody syndrome) were normal. These data are thus more consistent with sarcoidosis, which is associated with hypergammaglobulinemia, and less consistent with common variable immunodeficiency, which is characterized by panhypogammaglobulinemia. Nonetheless, we firmly agree with Dr. Cook that the clinical similarities between sarcoidosis and granulomatous common variable immunodeficiency probably reflect common pathophysiologic pathways and therefore suggest potentially overlapping therapeutic approaches. Animal models and human studies implicate TNF-␣ in the pathogenesis of granulomas. Mice deficient in either TNF-␣ or TNF receptor I exhibit impaired granuloma formation in response to bacterial antigens (1, 2); as pointed out by Dr. Cook and in our report, various lines of evidence suggest that active granulomatous disease in humans is associated with increased production of TNF-␣. It is therefore not surprising that certain features of granulomatous common variable immunodeficiency may respond to TNF-␣ inhibition (3) and that additional cases of refractory sarcoidosis responding to infliximab have been reported by Baughman and Lower (4).
Dr. O'Connor and colleagues warn of the potential exacerbation of occult Mycobacterium tuberculosis infections with anti-TNF-␣ therapies. We would extend this caution to include all types of infection, especially atypical ones such as other mycobacteria or fungi that may be more difficult to identify and may in fact mimic systemic inflammatory disorders. In our patient, corticosteroids and infliximab were not initiated until we were reasonably comfortable that infectious causes were excluded. Postlicensure reports of infections in the setting of infliximab and etanercept therapy have included tuberculosis, listeriosis, Pneumocystis carinii pneumonia, herpesvirus infections, and candidiasis (5). Vigilance and suspicion for active or latent infectious conditions are essential before, during, and after anti-TNF-␣ treatment, as they would be with any immunosuppressive therapy. Moreover, since TNF-␣ may contribute to tumor surveillance and immune tolerance, we further recommend that, with anticipated wider use of anti-TNF-␣ therapies, physicians must also maintain increased awareness of potential oncologic and autoimmune complications. 
Colitis Associated with Variant Clostridium difficile
TO THE EDITOR:
In their report of a case of fatal pseudomembranous colitis associated with a variant Clostridium difficile strain, Johnson and colleagues (1) did an impressive job of characterizing the toxin B-producing variant and emphasizing that "clinical laboratories and clinicians who rely solely on toxin A immunoassay to diagnose C. difficile disease should recognize the possibility of C. difficile diarrhea in patients with negative test results." The laboratory studies performed on the isolate were informative, and the telephone survey revealing that half of the hospitals in the Chicago, Illinois, area rely exclusively on the assay for toxin A provided a clear warning.
However, we believe that a simpler reminder is equally important. Subsequent to antibiotic use for an unrelated condition, the 86-year-old man discussed by Johnson and colleagues was followed for 2 months and had diarrhea, cramps, and sometimes fever. He had even had a positive culture for C. difficile. During that period, repeated tests (including computed tomography and colonoscopy that suggested pseudomembranous colitis) were performed-that is, there was an appropriately high degree of suspicion-but his illness was never treated. The current fashion of withholding treatment until there is laboratory proof of a diagnosis (with the goal, in part, of not "overusing" antibiotics) is contrary to logical medicine. If this patient had been prescribed oral cholestyramine after the first stool specimen had been obtained, there would have been no interference with the investigation and his symptoms would probably have been relieved in a day. If not, oral metronidazole or vancomycin could have been added, again with minimal risk and a high probability of control. They were not given. The patient died.
We need laboratories, but clinical judgment is still the key to good medicine. As for the idea that physicians should be criticized for starting antibiotics before laboratory "proof" of their appropriateness, one might revisit the 1974 comment by Eugene A. Stead Jr.: "I believe that the early and promiscuous prescribing of antibiotics has eliminated mastoiditis and acute staphylococcal osteomyelitis. I don't believe antibiotics given in accordance with scientific principles established by our leaders in infectious diseases would have accomplished this."
Quentin B. Deming, MD
Hanover, NH 03755-6600
Edward S. Hyman, MD New Orleans, LA 70125 IN RESPONSE: We appreciate the comments by Drs. Deming and Hyman and agree that laboratory testing should not replace clinical judgment. As we pointed out in our report, there were ample clinical clues to the diagnosis of C. difficile colitis that were ignored in light of the laboratory test results. We also agree that empirical therapy should be initiated in a seriously ill patient if the epidemiologic and clinical features are consistent with the diagnosis. Cholestyramine, however, is not recommended as a first-line therapy for C. difficileassociated diarrhea. Although there are anecdotal reports of success (1), binding resins such as colestipol did not appear more effective than placebo in a comparative clinical trial (2) . Furthermore, these resins may also bind antibiotics such as vancomycin (3) and should therefore not be used in combination for treatment of C. difficileassociated diarrhea.
It is important to perform diagnostic tests for C. difficile to confirm clinical diagnoses and guide the clinical management of patients, particularly because response to appropriate therapy often takes several days and relapse or recurrent infections are common (4) . As highlighted by our report, it is important to recognize the limitations of diagnostic testing or, to put it another way, the "tyranny of the test result," and use clinical judgment when laboratory test results deviate from clinical evidence. It is also important to appreciate the potential presence of variant strains of C. difficile to explain why toxin A test results may be unexpectedly negative. Since the publication of our report, we have been contacted by clinicians from two different states who also reported fatal cases of pseudomembranous colitis in which stool specimens were toxin A-negative and specific therapy for C. difficile was not initiated. Genotypic and phenotypic analyses of these strains are being conducted.
We agree that clinical judgment remains critical to optimum patient care. For practitioners, it is imperative to remember that even the best of immunologic assays for C. difficile toxins remain no more than 80% sensitive for laboratory confirmation of this disease (5 
Effect of Angiotensin-Converting Enzyme Inhibitors on Progression of Nondiabetic Renal Disease
TO THE EDITOR: In our article on angiotensin-converting enzyme (ACE) inhibitors and progression of nondiabetic renal disease (1), we stated that regimens containing ACE inhibitors are more effective in slowing the progression of nondiabetic renal disease than regimens that do not include them. Drs. Schrier and Estacio, in their accompanying editorial (2), consider our findings "an exciting hypothesis that warrants confirmation" and state that meta-analysis cannot produce definitive conclusions. Others have concluded, however, that a well-conducted meta-analysis of randomized clinical trials of individual patient data provides the highest level of evidence in support of a therapeutic intervention (3) .
All of the studies included in our meta-analysis, even the placebo-controlled studies, used concomitant antihypertensive agents to achieve a target blood pressure of less than 140/90 mm Hg. We reported the results separately for the five studies that compared ACE inhibitor groups and placebo groups, as well as for the six studies that compared ACE inhibitor groups and nonplacebo groups. The results were not substantially different from each other or from the results in the entire group. This justifies the pooling of both types of studies and should allay concern that inclusion of placebo-controlled studies biased our results.
We agree that our meta-analysis has not answered all relevant questions and that additional studies would be useful to confirm some of our hypotheses. However, we do not think that clinicians need to wait for completion of additional studies before following our recommendation that ACE inhibitors are indicated for treatment of nondiabetic patients with chronic renal disease and proteinuria, and possibly those without proteinuria.
Tazeen H. Jafar, MD, MPH
